Compounds > erlotinib hydrochloride

Page last updated: 2024-09-05

erlotinib hydrochloride and Leukemia, Myeloid, Acute

erlotinib hydrochloride has been researched along with Leukemia, Myeloid, Acute in 16 studies

Research

Studies (16)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (25.00)	29.6817
2010's	11 (68.75)	24.3611
2020's	1 (6.25)	2.80

Authors

Authors	Studies
Cao, ZX; Guo, CJ; He, JL; Li, YZ; Peng, C; Peng, F; Song, X; Tan, L; Yu, S; Zhang, RQ	1
Abou Dalle, I; Alvarado, Y; Borthakur, G; Cortes, JE; Diaz Duque, A; Estrov, Z; Ferrajoli, A; Gandhi, V; Jabbour, E; Kantarjian, HM; Konopleva, M; Lamothe, B; Pemmaraju, N; Pinnamaneni, P; Randhawa, J; Ravandi, F; Wierda, WG	1
Fenaux, P; Galluzzi, L; Kepp, O; Kroemer, G; Lainey, E; Micol, JB; Sukkurwala, AQ; Wolfromm, A	1
Fulp, WJ; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Rodriguez, Y; Tinsley, S; Yu, D	1
Adès, L; Beyne-Rauzy, O; Boehrer, S; Chermat, F; Delaunay, J; Fenaux, P; Hunault, M; Jourdan, E; Kroemer, G; Prebet, T; Raffoux, E; Sebert, M; Seegers, V; Thepot, S; Wattel, E	1
Amin, C; Cangany, M; Cripe, LD; Czader, M; Konig, H; Sayar, H	1
Al-Awar, R; Aman, A; Datti, A; Gronda, M; Hurren, R; Lin, FH; MacLean, N; Minden, MD; Rotin, LE; Schimmer, AD; Wang, X; Wrana, JL	1
Adès, L; Boehrer, S; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Kroemer, G; Tailler, M; Tajeddine, N	1
Altavilla, G; Arrigo, C; Pitini, V	1
Freidlin, B; Korn, EL; McShane, LM	1
Adès, L; Boehrer, S; Bouteloup, C; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Harper, F; Kroemer, G; Lainey, E; Pierron, G; Sébert, M; Tailler, M; Thépot, S	1
Daub, H; Schreiber, TB; Weber, C	1
Bouteloup, C; De Botton, S; Enot, D; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Marie, N; Micol, JB; Scoazec, M; Wolfromm, A	1
Bouteloup, C; De Botton, S; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Scoazec, M; Sébert, M; Thépot, S	1
Chan, G; Pilichowska, M	1
Adès, L; Boehrer, S; Braun, T; de Botton, S; Fabre, C; Fenaux, P; Galluzzi, L; Gardin, C; Grosjean, J; Kroemer, G; Le Roux, G; Martin, A	1

Trials

3 trial(s) available for erlotinib hydrochloride and Leukemia, Myeloid, Acute

Article	Year
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta haematologica, 2018, Volume: 140, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Young Adult	2018
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. American journal of hematology, 2014, Volume: 89, Issue:8 Topics: Administration, Oral; Aged; Antineoplastic Agents; Azacitidine; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure	2014
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. Leukemia research, 2014, Volume: 38, Issue:12 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Remission Induction	2014

Other Studies

13 other study(ies) available for erlotinib hydrochloride and Leukemia, Myeloid, Acute

Article	Year
Erlotinib is effective against FLT3-ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020, Volume: 34, Issue:8 Topics: Animals; Biomarkers, Tumor; Bone Marrow; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; src-Family Kinases; Tandem Repeat Sequences; THP-1 Cells	2020
EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells. Cell cycle (Georgetown, Tex.), 2013, Sep-15, Volume: 12, Issue:18 Topics: Antigens, CD34; CD11b Antigen; Cell Cycle Checkpoints; Cell Differentiation; Cholecalciferol; ErbB Receptors; Erlotinib Hydrochloride; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 14; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Tretinoin; Tumor Cells, Cultured	2013
Pilot study of erlotinib in patients with acute myeloid leukemia. Leukemia research, 2015, Volume: 39, Issue:2 Topics: Aged; Aged, 80 and over; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Pilot Projects; Protein Kinase Inhibitors; Quinazolines	2015
Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells. Haematologica, 2016, Volume: 101, Issue:11 Topics: Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Ethacridine; Glycoside Hydrolases; Humans; Leukemia, Myeloid, Acute	2016
Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison. Biochemical pharmacology, 2008, Dec-01, Volume: 76, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Differentiation; Cell Line, Tumor; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines	2008
Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-20, Volume: 26, Issue:21 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Quinazolines; Smoking; Tomography, X-Ray Computed	2008
Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute, 2010, Feb-03, Volume: 102, Issue:3 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; DNA-Binding Proteins; Endonucleases; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Staurosporine	2010
Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. Cell cycle (Georgetown, Tex.), 2011, Sep-15, Volume: 10, Issue:18 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Enzyme Activation; Erlotinib Hydrochloride; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Microscopy, Electron; Microscopy, Fluorescence; Microtubule-Associated Proteins; Phosphorylation; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; src-Family Kinases; Stilbenes; TOR Serine-Threonine Kinases	2011
Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. Journal of proteomics, 2012, Feb-02, Volume: 75, Issue:4 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mass Spectrometry; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction	2012
Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene, 2013, Sep-12, Volume: 32, Issue:37 Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Line, Tumor; DNA Damage; Drug Synergism; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines	2013
Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell cycle (Georgetown, Tex.), 2012, Nov-01, Volume: 11, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Down-Regulation; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Quinazolines	2012
Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. Blood, 2007, Aug-01, Volume: 110, Issue:3 Topics: Aged; Carcinoma, Small Cell; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines; Remission Induction	2007
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood, 2008, Feb-15, Volume: 111, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Reference Values	2008